熱門資訊> 正文
Vericel获得FDA批准NexoBrid用于儿科烧伤患者
2024-08-16 04:39
- Vericel (NASDAQ:VCEL) has received FDA approval for its burn care therapy NexoBrid in the treatment of children with severe thermal burns.
- NexoBrid was approved for the removal of eschar, or dead tissue, in pediatric patients with deep partial-thickness and/or full-thickness thermal burns.
- Vericel (VCEL) said it is expanding its customer base to include approximately 20 pediatric burn centers in the U.S.
- The product was approved by the FDA for the treatment of adult patients in December 2022, according to a statement.
More on Vericel
- Vericel Corporation (VCEL) Q2 2024 Earnings Call Transcript
- Vericel GAAP EPS of -$0.10 misses by $0.01, revenue of $52.66M beats by $0.07M
- Seeking Alpha’s Quant Rating on Vericel
- Historical earnings data for Vericel
- Financial information for Vericel
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
